Nanosphere's BC-GP test reduces hospital stay, costs

Researchers at University of Florida Health Jacksonville reported data from 74 in-patients with enterococcal bacteremia showing that implementation of the Verigene Gram-Positive Blood Culture (BC-GP) Nucleic Acid test from Nanosphere Inc. (NASDAQ:NSPH) significantly reduced mean hospital length of stay (43.2 vs. 21.5 days, p=0.0484) and mean hospital costs by $60,729 ($103,075 vs. $42,346, p=0.02) compared to not using the test. Additionally, Nanosphere said there was complete agreement between BC-GP test results and results derived from conventional culture and susceptibility methods, plus a significant reduction of 47.5 hours in the time to reporting of the test results. Data were published in the Journal of Clinical Microbiology. ...